trending Market Intelligence /marketintelligence/en/news-insights/trending/EnTfKMz8UQFcYvToD0o1KQ2 content esgSubNav
Log in to other products


Looking for more?

Contact Us
In This List

Bellicum Pharmaceuticals director steps down; replacement named


Global M&A Infographic Q1 2021


Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge


COVID-19 Impact & Recovery: Private Equity

COVID-19 Impact & Recovery: Corporates

Bellicum Pharmaceuticals director steps down; replacement named

Frank McGuyer stepped down from Bellicum Pharmaceuticals Inc.'s board, effective Dec. 20, after serving on the board for nine years.

In connection with McGuyer's resignation, the company appointed Judith Klimovsky to its board, effective the same date.

Klimovsky currently serves as executive vice president and chief development officer of Genmab A/S, an international biotechnology company developing antibody therapeutics for cancer.

Houston-based Bellicum Pharmaceuticals is a clinical-stage biopharmaceutical company that develops novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders.